HC Wainwright Forecasts TG Therapeutics FY2025 Earnings

TG Therapeutics, Inc. (NASDAQ:TGTX) – Stock analysts at HC Wainwright raised their FY2025 EPS estimates for TG Therapeutics in a research report issued to clients and investors on Wednesday, January 14th. HC Wainwright analyst E. Bodnar now expects that the biopharmaceutical company will post earnings of $2.89 per share for the year, up from their prior forecast of $2.83. HC Wainwright has a “Buy” rating and a $60.00 price target on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for TG Therapeutics’ Q4 2026 earnings at $0.47 EPS, FY2026 earnings at $1.28 EPS, FY2028 earnings at $2.38 EPS, FY2029 earnings at $3.02 EPS and FY2030 earnings at $3.96 EPS.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $2.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $2.19. The business had revenue of $161.71 million for the quarter, compared to the consensus estimate of $152.12 million. TG Therapeutics had a return on equity of 133.24% and a net margin of 84.13%.The business’s revenue was up 92.7% compared to the same quarter last year. During the same period last year, the business posted $0.02 EPS.

TGTX has been the subject of several other reports. The Goldman Sachs Group increased their price target on shares of TG Therapeutics from $37.00 to $39.00 and gave the company a “neutral” rating in a research report on Thursday. Wall Street Zen raised shares of TG Therapeutics from a “hold” rating to a “buy” rating in a research report on Sunday, December 14th. B. Riley upgraded shares of TG Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 4th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of TG Therapeutics in a research report on Monday, December 29th. Finally, JPMorgan Chase & Co. increased their price objective on TG Therapeutics from $46.00 to $49.00 and gave the company an “overweight” rating in a report on Monday, November 3rd. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, TG Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $50.75.

TG Therapeutics Price Performance

Shares of TGTX stock opened at $29.54 on Thursday. The stock’s 50-day moving average is $30.85 and its 200 day moving average is $32.58. TG Therapeutics has a 1-year low of $25.28 and a 1-year high of $46.48. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.82 and a quick ratio of 2.89. The company has a market cap of $4.69 billion, a P/E ratio of 10.63 and a beta of 1.86.

Hedge Funds Weigh In On TG Therapeutics

Several hedge funds have recently made changes to their positions in the company. Jump Financial LLC grew its holdings in TG Therapeutics by 551.8% during the second quarter. Jump Financial LLC now owns 320,022 shares of the biopharmaceutical company’s stock worth $11,518,000 after acquiring an additional 270,922 shares during the period. Marex Group plc purchased a new stake in TG Therapeutics in the 2nd quarter worth approximately $10,017,000. Strs Ohio acquired a new stake in shares of TG Therapeutics during the 1st quarter worth approximately $785,000. KLP Kapitalforvaltning AS grew its stake in shares of TG Therapeutics by 7.7% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 30,800 shares of the biopharmaceutical company’s stock worth $1,108,000 after purchasing an additional 2,200 shares during the period. Finally, Yorktown Management & Research Co Inc purchased a new position in shares of TG Therapeutics during the 2nd quarter valued at approximately $383,000. 58.58% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Yann Echelard sold 5,000 shares of TG Therapeutics stock in a transaction on Monday, November 24th. The shares were sold at an average price of $32.57, for a total transaction of $162,850.00. Following the completion of the sale, the director directly owned 223,816 shares in the company, valued at approximately $7,289,687.12. The trade was a 2.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 10.64% of the company’s stock.

TG Therapeutics News Roundup

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: Preliminary Q4 and full‑year 2025 net product revenue beat internal guidance and the company gave a positive 2026 revenue outlook, helping push shares higher; analysts and investors highlighted upcoming Briumvi pipeline milestones as additional upside. TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results
• Positive Sentiment: Company press release / investor communications reiterated preliminary Q4/2025 figures and 2026 guidance and listed anticipated development milestones — this official disclosure underpins the market’s positive reaction. TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones
• Positive Sentiment: Retail-trader interest and flow/momentum amplified gains: media coverage notes retail buying, and options activity showed a large surge in call purchases (≈7,870 calls, ~119% above normal), consistent with short‑term bullish positioning. Retail traders are piling into TG Therapeutics – what’s driving the chatter?
• Neutral Sentiment: TGTX presented at the J.P. Morgan Healthcare Conference (transcript available) — useful for pipeline/management color but no single market‑moving revelation in the transcript itself. TGTX Presents at 44th Annual J.P. Morgan Healthcare Conference — Transcript
• Neutral Sentiment: Database entries show the company “updated” FY2025 and FY2026 EPS guidance but the published entries here lack specific EPS numbers — until full guidance details are confirmed, impact is unclear.
• Negative Sentiment: HC Wainwright trimmed several forward EPS estimates (Q4‑2026 cut to $0.47 from $0.51; modest cuts to FY2026, FY2028, FY2029 forecasts) — the revisions are small but introduce some downward pressure on longer‑term expectations. HC Wainwright nevertheless retains a Buy rating and $60 price target, which tempers the downgrade impact.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.